News | June 17, 2008

Radiation Dosage Based on BMI Advances Personalized Medicine

June 18, 2008 - In a new study presented at SNM’s 55th Annual Meeting, technologists are using body mass index (BMI), instead of body weight, to provide patients optimal dosing of 18-fluoro-2-deoxyglucose (FDG), a radiopharmaceutical commonly used in oncology imaging.

BMI is a calculation that takes into account both a patient’s weight and height. Traditionally, only a patient’s weight has been taken into consideration when prescribing appropriate dosage of radiopharmaceuticals for positron emission tomography (PET) and computed tomography (CT) scans.

“Using BMI allows us to more specifically adjust dosing to individual patients,” said Sarah Krumrey, a technologist in the Department of Nuclear Medicine at St. Louis University Hospital, St. Louis, Mo., and lead author of the study, Should FDG Dose Be Based on BMI Instead of Body Weight? presented at SNM’s 55th Annual Meeting, June 14–18 in New Orleans.

Current procedures for PET/CT scans with FDG use a patient’s weight as the main factor in determining the appropriate dose. The goal of this study was to compare changes in PET/CT image quality as a result of switching from a weight-adjusted to a BMI-adjusted FDG dose. A BMI-adjusted dose was used in a total of a 104 patients undergoing PET/CT exams for known or suspected cancer. In this double-blinded study, PET/CT scans were reviewed and graded to access the image quality. Switching to a BMI-adjusted dose resulted in improved image quality and lower required dosage of 18-FDG.

“Based on our study, we believe that adjusting the FDG dose according to a patient’s BMI could lead to new imaging protocols,” added Krumrey. “The results of this study—which takes into account individual patient factors—could further advance personalized medicine,” said Krumrey. “Unlike a blanket approach, this allows us to avoid unnecessary dosing and better treat the patients in our care.”

Scientific Paper 2010: S.A. Krumrey, I. Tran, P. Yost, D. Oliver, N. Nhuyen, M. Osman, F. Qazi, Nuclear Medicine, St. Louis University Hospital, St. Louis, Mo.: “Should FDG Dose Be Based on BMI Instead of Body Weight?” SNM’s 55th Annual Meeting, June 14–18, 2008.

For more information: visit www.snm.org.

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init